Show simple item record

dc.contributor.authorLiu, Mei
dc.contributor.authorHuang, Pei
dc.contributor.authorWang, Qian
dc.contributor.authorRen, Biao
dc.contributor.authorOyeleye, Ayokunmi
dc.contributor.authorLiu, Miaomiao
dc.contributor.authorZhang, Jingyu
dc.contributor.authorLi, Xiaolin
dc.contributor.authorZhang, Xiaoping
dc.contributor.authorZhang, Lixin
dc.contributor.authorLiu, Xueting
dc.date.accessioned2020-12-03T01:28:55Z
dc.date.available2020-12-03T01:28:55Z
dc.date.issued2017
dc.identifier.issn0021-8820
dc.identifier.doi10.1038/ja.2016.160
dc.identifier.urihttp://hdl.handle.net/10072/399868
dc.description.abstractMulti-drug resistance of pathogenic microorganisms is a serious threat to human health. In particular, Candida albicans, the most common opportunistic clinical fungal pathogen is one of the major causes of systemic infections, resulting in an estimated 30% of severe fungal infections, with mortality rate reaching nearly 40%.1, 2 Widespread and repeated use of current drugs, particularly azoles, have contributed to the rapid occurrence of antifungal drug resistance,3, 4 and most screening approaches for new drugs which target essential genes and fungal pathogens are likely to generate resistance over time. Given the high mortality rate resulting from fungal infections in immunocompromised patients and the limited number of highly effective, yet safe treatment agents, the development of new antifungal therapeutics is critical.1, 2, 5 A strategy limiting the pressure on drug targets would increase the lifespan of antifungal agents and reduce the frequency of treatment failures.3, 6 For instance, using synergistic drugs aimed at more than one target and slowing down the emergence of drug-resistant pathogens will be one of the key approaches to antifungal therapy. Our research group demonstrated that beauvericin (BEA) showed strong synergism with ketoconazole against diverse fungal pathogens both in vitro and in vivo,5 and that this synergetic effect was not caused by their pharmacokinetic interaction.7
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.ispartofpagefrom715
dc.relation.ispartofpageto717
dc.relation.ispartofissue5
dc.relation.ispartofjournalThe Journal of Antibiotics
dc.relation.ispartofvolume70
dc.subject.fieldofresearchMicrobiology
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchcode3107
dc.subject.fieldofresearchcode3214
dc.titleSynergistic antifungal indolecarbazoles from Streptomyces sp. CNS-42 associated with traditional Chinese medicine Alisma orientale
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationLiu, M; Huang, P; Wang, Q; Ren, B; Oyeleye, A; Liu, M; Zhang, J; Li, X; Zhang, X; Zhang, L; Liu, X, Synergistic antifungal indolecarbazoles from Streptomyces sp. CNS-42 associated with traditional Chinese medicine Alisma orientale, The Journal of Antibiotics, 2017, 70 (5), pp. 715-717
dc.date.updated2020-12-02T23:35:09Z
gro.hasfulltextNo Full Text
gro.griffith.authorLiu, Miaomiao


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record